The near-term binary catalyst is the ABTECT Phase 3 UC maintenance top-line data, expected within ~4-6 weeks. Positive data would de-risk NDA submission pathway and likely drive a re-rating. Failure would significantly impair the asset's value. The cash position through Q4 2027 is sufficient to cover ongoing operations and clinical programs through key milestones, including the Phase 3 readout.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 26 $126.41entry
- T+1 · 6mo ago +2.94%α +2.99% · $130.13
- T+5 · 6mo ago +2.59%α +1.51% · $129.69
- T+20 · 5mo ago −25.63%α −23.68% · $94.01
- T+60 · 3mo ago −4.63%α −7.35% · $120.56
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Abivax reported Q1 2026 net loss of €48.5M (vs €52.4M loss in Q1 2025) with operating loss of €56.2M. The press release highlights durable Phase 2 clinical remission data (68% at week 144 on 25mg de-escalation) and €491.6M cash runway into Q4 2027. The company is pre-revenue with a biotech pipeline catalyst, the ABTECT Phase 3 UC maintenance trial top-line results due late Q2 2026 is the near-term binary event.
Key Facts
- Operational loss of €56.2M in Q1 2026 vs €47.2M in Q1 2025
- Net loss of €48.5M vs €52.4M year-over-year (improved by financial gain)
- Cash, cash equivalents and short-term investments of €491.6M as of March 31, 2026
- Cash runway projected into Q4 2027
- Phase 3 ABTECT-UC maintenance trial top-line results expected late Q2 2026
- 130 patients de-escalated to 25mg obefazimod; 68% in clinical remission at week 144 (ITT)
- NDA submission for obefazimod in UC planned for Q4 2026 (subject to positive data)
- Phase 2b CD induction trial top-line results expected Q4 2026
- R&D spend increased 26% YoY to €49.5M, driven by new indications and CD program
- Equity offering of $45M (€38.5M) ADS completed May 5, 2026
Financial Impact
Pre-revenue clinical biotech, no revenue to evaluate. Q1 2026 operating loss €56.2M vs €47.2M in Q1 2025; net loss improved by financial gain (€8.0M vs -€5.2M). Cash burn from operations was €50.5M in Q1 2026 vs €33.3M in Q1 2025.
Risk Factors
- Phase 3 ABTECT-UC maintenance trial may fail to meet endpoints, binary risk for the stock near-term
- Pre-revenue stage with high cash burn rate (€50.5M operating cash outflow in Q1 2026)
- Dilution risk from ADS offering completed May 5, 2026 ($45M)
- Regulatory and commercial execution risk for obefazimod in UC and CD indications
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300344 |
Track record
10 reports on ABVX
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +33.05% at T+60 after the Jul 2, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $83.40 Now $83.61 +0.25% settles Nov 24
- Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $86.59 to $85.73 Now $83.61 −3.44% ▼ −0.99% +1.71% vs SPY
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $130.00 to $121.45 Now $83.61 −35.68% ▼ −6.58% −7.79% vs SPY
- Jul 2, 202619w ago 6-K Bearish 6/10 Entry $144.65 to $140.74 Now $83.61 +42.20% ▲ +2.70% +3.63% vs SPY
- Jul 2, 202619w ago 424B5 Bearish 6/10 Entry $144.65 to $140.74 Now $83.61 +42.20% ▲ +2.70% +3.63% vs SPY
- Jul 1, 202619w ago Press Release Bearish 6/10 Entry $132.56 to $142.17 Now $83.61 +36.93% ▼ −7.25% −6.99% vs SPY
- Jun 29, 202620w ago 6-K Bullish 7/10 Entry $133.26 to $143.99 Now $83.61 −37.26% ▲ +8.05% +7.45% vs SPY
- Jun 29, 202620w ago Press Release Bullish 7/10 Entry $133.26 to $143.99 Now $83.61 −37.26% ▲ +8.05% +7.45% vs SPY
- May 22, 202625w ago Press Release Neutral 5/10 Viewing Entry $126.41 to $129.69 Now $83.61 −33.86% ▲ +2.59% +1.51% vs SPY
- Mar 23, 202634w ago Press Release Mixed 6/10 Entry $110.17 to $111.35 Now $83.61 −24.11% ▲ +1.07% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers